期刊文献+

6O例原发性胆汁性肝硬化患者的临床与病理特征及预后分析 被引量:8

Liver histopathology, clinical features and prognostic factors of primary biliary cirrhosis: an analysis of 60 cases
原文传递
导出
摘要 目的了解原发性胆汁性肝硬化患者的临床与病理特征及影响生存的危险因素。方法分析60例原发性胆汁性肝硬化患者的一般资料、临床表现、生物化学、免疫学及病理学改变。患者全部定期随访,选择年龄、性别、白蛋白、胆红素、肝组织学分期5个可能对该病预后产生影响的研究因素,通过Cox比例风险模型对患者预后进行多因素分析。结果60例PBC患者中,女性与男性之比为4:1,平均年龄(52.5±9.4)岁。临床主要表现为黄疸(61.6%)、乏力(51.6%)、纳差(43.3%)、皮肤瘙痒(25%)。88.3%(53/60)的患者血清碱性磷酸酶及γ-谷氨酰转肽酶水平明显升高,分别为(242.3±137.1)U/L和(250.6±216.1)U/L,而血清ALT、AST水平仅轻或中度升高,分别为(185.8±269.1)U/L和(172.5±163.6)U/L,53.3%(32/60)的患者血清总胆红素≥34.2μmol/L,59.6%(28/47)的患者血清IgM升高,68.3%的患者(41/60)线粒体抗体和(或)线粒体抗体M2亚型阳性。有42例患者行肝脏病理学检查,早期(I、Ⅱ期)占33.3%,晚期(Ⅲ、Ⅳ期)占66.6%。随访:5例死亡,死亡原因为肝功能衰竭(3例)或上消化道出血(2例),45例生存,10例失访,平均生存期为3.92年。Cox多因素分析表明,影响预后的独立因素是年龄、胆红素、肝组织学分期。结论提高原发性胆汁性肝硬化的早期诊断,给予及时有效治疗,可改进预后和生存质量。 Objective Clinical and liver pathological features of 60 primary biliary cirrhrosis (PBC) patients were reviewed to identify prognostic factors in order to improve the diagnosis and treatment of the disease. Methods The general conditions, clinical manifestations, serum biochemical and immunological changes, and liver pathological findings were assessed in 60 PBC patients. All cases were followed up and 5 variables were studied by univariate analysis; the variables linked with survival were included in a Cox model. Results Forty-eight patients were females (80%), 12 were males (20%), and the mean age at their diagnoses was (52.5±9.4). The symptoms most frequently complained about were jaundice (61.6%), fatigue (51.6%), anorexia (43.3%) and pruritus (25%). Serum alkaline phosphatase (ALP) and glutamyl transpeptidase (GGT) levels were markedly elevated in the majority of the patients [(242.3±137.1) U/L and (250.6± 216.1 ) U/L, respectively], whereas ALT and AST levels were mildly to moderately elevated [( 185.8±269.1) U/L and (172.5±163.6) U/L, respectively]. Thirty-two patients (53.3%) had a total bilirubin level of ≥34.2μmol/L. Twenty-eight patients (59.5%) had elevated serum IgM and 41 patients (68.3%) were anti-mitochondrial antibody AMA/AMA-M2 positive. Forty-two of the 60 patients had liver biopsies. The liver pathological changes: 33.3% of the cases were in I or Ⅱ stage and 66.6% in Ⅲ or Ⅳ stage. The follow up results: Five patients died of liver failure or massive upper gastrointestinal bleeding; 45 were still alive; the average survival peroid was 3.92 years; 10 patients were lost in the follow-up. With multivariate analysis (Cox model), age, level of total bilirubin and the stage of the liver pathological changes were found to be independent factors finked to the survival of the patients. Conclusion PBC may not be a rare liver disease in China. The awareness to recognize PBC is important in making an early diagnosis and treatment.
出处 《中华肝脏病杂志》 CAS CSCD 北大核心 2008年第6期457-460,共4页 Chinese Journal of Hepatology
关键词 肝硬化 胆汁性 病理学 临床 预后 Liver cirrhosis, biliary Pathology, clinical Prognosis
  • 相关文献

参考文献12

二级参考文献27

  • 1陈嵩,王宇明.自身免疫重叠综合征[J].世界华人消化杂志,2005,13(15):1875-1878. 被引量:7
  • 2[1]Walker JG, Doniach D, Roitt IM, et al. Serological tests in the diagnosis of primary biliary cirrhosis. Lancet, 1965:827-830.
  • 3[2]Fussey S, Guest JR, James O, et al. Identification and analysis of the major M2 autoantigens in primary billiary cirrhosis. Proc Natl Acad Sci USA, 1988, 85:8654-8658.
  • 4[3]Klein R, Berg PA. Significance of antimitochondrial antibody profiles in primary biliary cirrhosis. In: Lindon KD, Heathcote EJ, Poupon R, eds. Primary biliary cirrhosis: From pathogenesis to clinical treatment. Dordrecht, Netherland, Kluser Academic Pub, 1998. 24-34.
  • 5[4]Bassendine MF, Jones DE, Yeaman SJ. Biochemistry and autoimmune response to the 2-oxacid dehydrogonase complexes in primary biliary cirrhosis. Semin Liver Dis, 1997, 17:49-60.
  • 6[5]Leung PSC, Coppel RL, Ansari A, et al. Antimitochondrial antibodies in primary billiary cirrhosis. Semin Liver Dis, 1997, 17:61-69.
  • 7[6]Sherlock S, Dooley J. Diseases of the liver and biliary system. 11 th ed. Oxford UK, Blackwell Science, 2002. 242.
  • 8[7]Zein CO, Boe GM, Donlinger J, et al. The role of liver biopsy in the diagnosis of primary biliary cirrhosis. Hepatology, 2001, 34: pt2,343A.
  • 9Heathcote EJ.Management of primary biliary cirrhosis.The Ameri.can Association for the Study of Liver Discases practice guidelines.Hepatology,2000.31:1005-1013.
  • 10Kadokawa Y.Omagari K.Hazama H.et al.Evaluation of newly devcloped ELISA using "MESACUP-2 test mitochondrial M2"kit for the diagnosis of primary biliary cirrhosis.Clin Biochem,2003.36:203-210.

共引文献172

同被引文献56

  • 1无.慢性乙型肝炎防治指南[J].实用肝脏病杂志,2006,9(1):8-18. 被引量:825
  • 2Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):161-163. 被引量:1510
  • 3廖锦元,黄仲奎,龙莉玲,黎宁钦.16层螺旋CT体积测量评估肝硬化肝叶大小的价值[J].临床放射学杂志,2006,25(5):425-428. 被引量:34
  • 4杨志国,许家璋,李平,韩振红,郭银燕.49例慢性丙型肝炎临床病理分析的启示[J].中国现代医学杂志,2006,16(12):1909-1910. 被引量:4
  • 5陈灏珠,林果为.实用内科学[M].13版.北京:人民卫生出版社,2009:919.
  • 6Pinter M, Sieghart W, Graziadei I, et al. Sorafenib in unreseetable hepa- tocellular carcinoma from mild to advanced stage liver cirrhosis [ J ]. On- cologist, 2009, 14(1): 70-76.
  • 7Kharaziha P, Hellstr,m PM, Noorinayer B, et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-If clinical trial [ Jl. Eur J Gastroenterol Hepa- tol, 2009, 21(10): 1199-1205.
  • 8Motosugi U, 2Ichikawa T, 2Sou H, 2et al. H, 2et al. Multi-or- gan perfusion CT in the abdomen using a 320-detector row CT scanner: preliminary results of perfusion changes in the liver, 2spleen, 2and pancreas of cirrhotic patients [ J ]. Eur J Radiol,22012, 281(10): 2533-2357.
  • 9余瑶.重组蛋白及合成肽抗原在戊型肝炎病毒感染诊断中的应用[J].国际病毒学杂志,2003,27(1):23-24.
  • 10Zhang XJ, 2Kanamatsu M, 2Zhou XR, 2et al. Differemtation of cirrhosis by using 3D hepatic volume ratio of LTW in multi-detector row CT scans and MR imaging. International Congress Series, 22005, 21281: 1163-1168.

引证文献8

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部